PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.21%
Both companies show declining cash positions (-13.21% vs AVXL's -3.71%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.21%
Cash + STI yoy ≥ 1.5x AVXL's -3.71%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.76%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-11.17%
≥ 1.5x AVXL's -2.84%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
7.73%
Higher PP&E (Net) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both AVXL and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.08%
Below half of AVXL's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
≥ 1.5x AVXL's -2.84%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-100.00%
Less than half of AVXL's 38.26%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of AVXL's 106.56%. Michael Burry suspects a big gap in pre-sales traction.
1577.51%
Less than half of AVXL's -81.99%. David Dodd sees fewer expansions in other current obligations.
-26.01%
Less than half of AVXL's 29.71%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of AVXL's 64.99%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-6.06%
Less than half of AVXL's 29.71%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.82%
0.5-0.75x AVXL's -5.28%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Less than half of AVXL's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-13.95%
≥ 1.5x AVXL's -5.17%. David Dodd sees stronger capital base growth than competitor.
-10.65%
≥ 1.5x AVXL's -2.84%. David Dodd sees faster overall balance sheet growth than competitor.
-100.00%
Both AVXL and the company show zero Total Investments Growth.
-4.69%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
13.42%
Above 1.5x AVXL's 3.71%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.